MRKMerck Sharp & Dohme LLCFinished
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study
Colorectal Cancer
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 94 (final count)
- Started
- Jun 14, 2022
- Main results expected
- Aug 15, 2024
- Fully finished
- Feb 21, 2025
- Results posted
- Sep 17, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival (OS)
Measured over: Up to approximately 26 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05600309 · record last updated 2025-11-26 · checked 2026-11-09 15:47 UTC